儿童人类免疫缺陷病毒/艾滋病的治疗

在过去的 15年 ,儿童人类免疫缺陷病毒 (humanimmun odeficiencyvirus,HIV)治疗策略有了很大变化 ,从单一用药发展到 3类抗逆转录病毒药物的联合治疗。高效抗逆转录病毒治疗 (highactiveanti retroviraltherapy ,HAART)俗称“鸡尾酒疗法” ,是指抗HIV药物的联合治疗 ,包括蛋白酶抑制剂(proteaseinhibitor ,PI)在内的 2种或多种药物的联合应用[1,2 ] 。联合用药比单一用药更能迅速有效地控制HIV复制 ,减少剂量及毒副作用 ,防止耐药株产生。虽然儿童与成人HIV感染的发病机制及抗逆转录病毒药物应用的病毒学及免疫学原则是相似的 ,但对…     

小儿人类免疫缺陷病毒感染/艾滋病的实验室诊断

艾滋病 (acquiredimmunodeficiencysyndrome,AIDS)是由人类免疫缺陷病毒 (humanimmunodeficiencyvirus,HIV)感染引起的一种传染病。自 1981年美国首次报告该病以来AIDS已在全球广泛流行。目前全球已有 4 0 0 0万以上人口感染HIV ,尤其是许多无辜儿童也不幸受染。根据联合国艾滋     

小儿人类免疫缺陷病毒感染/艾滋病诊断及处理建议

艾滋病即获得性免疫缺陷综合征 (acquriedimmunodefi ciencysyndrome ,AIDS) ,是由人类免疫缺陷病毒 (humanim munodeficiencyvirus ,HIV)感染所致的一种传播迅速、病死率极高的恶性病。我国目前HIV感染人群已超过 10 0万 (2 0 0 2年 ) ,且大多数集中在生育期成人。如果控制不好 ,10年后HIV感染者可能超过 10 0 0万。HIV感染母婴传播率高达2 2 %～ 6 5 %。小儿HIV感染发生率增长较成人快、潜伏期短、疾病进展快、死亡率高。因此小儿HIV感染 /艾滋病防治已是我国儿科所面临的严峻挑战和紧迫任务。本建议适用于各级儿科医疗机构对HI…     

Tuberculosis in children with acquired immunodeficiency syndrome

With AIDS related tuberculosis in the pediatric population on the rise, we review our experience with 14 such children. A brief review of the pertinent literature is also presented. Received: 20 March 1996 Accepted: 25 June 1996     

Epidemiology of acquired immunodeficiency syndrome and human immunodeficiency virus infection in adolescents

The epidemiology of acquired immunodeficiency syndrome (AIDS) and human immunodeficiency virus infection (HIV) in adolescents is important for purposes of prevention and car, since sexual and drug behavior is formed during this period. For 1990 the Centers for Disease Control reports .4% of AIDS cases are among adolescents 13-19 years old; this figure has steadily risen since 1982. 53% of the reported AIDS cases were from New York, Florida, California, Texas, Puerto Rico, and New Jersey, and has remained stable since 1984. 72% were from metropolitan areas of 1 million population, with a small decreasing trend between 1986-88. 75% of reported cases occurred between 17-19 years, and usually among males (80%) and ethnic minorities (36% African Americans and 18% Hispanics). The sex ratio dropped from 4:1 to 3:1 in 1988. Modes of transmission; indicator diseases and mortality; HIV seroprevalence data; risk of HIV transmission in adolescents; knowledge, attitudes, beliefs, and behavior; research needs; and prevention are discussed. From the studies available, it is reported that adolescents are aware that sexual intercourse and sharing IV drug needles are the main modes of HIV transmission. HIV transmission is more likely to be associated with homosexual contact. Misconceptions are that one could tell if a person were infected with HIV. Knowledge does not always translate to appropriate behavior. Perceived risk does decrease risky behavior, i.e., through abstinence or condom use. More information was desired. Research needs were identified as lagging behind present knowledge of children and adults, and necessary in clinical, epidemiologic, behavioral, and prevention aspects. The natural history of infection is limited to studies of hemophilia, where infected adolescents may have a lower rate of progression to AIDS or a longer incubation period or higher tolerance to severe immunodeficiency. Questions arise concerning the unique factors, such as hormonal changes, that influence the clinical course of the infection. Health care models need to be assessed. Identification of subpopulations that are at the highest risk is needed, i.e., the influence of the crack cocaine epidemic on HIV transmission. Prevention is seen in terms of new creative approaches, comprehensive school and nonschool health education, and behavioral techniques to avoid risky behavior throughout the health community.     

Nephrotic syndrome associated with acquired immunodeficiency syndrome in children

We report here the cases of 15 children in whom nephrotic syndrome developed, from among 164 children (55% male, 90% black) followed in our acquired immunodeficiency syndrome clinic from 1984 through 1990. Mean age at onset of nephrotic syndrome was 4.9 +/- 2.6 years. Fourteen patients were black and one was Hispanic. Seventy-three percent of our patients with nephrotic syndrome were girls. The mean duration of clinical acquired immunodeficiency syndrome before development of nephrotic syndrome was 1.7 +/- 1.1 years. In eight patients, nephrotic syndrome appeared between 3 and 11 months after intravenous infusions of immune globulin or albumin were administered as part of a research protocol; this incidence (8/47) was higher than the incidence of nephrotic syndrome among those who did not receive intravenous infusions (7/117, p less than 0.05). Tissue for histologic examination was available for 80% of the patients, and histologic examination demonstrated mesangial hypercellularity (5 patients), focal segmental glomerulosclerosis (4 patients), minimal change disease (2 patients), and IgM nephropathy (1 patient). Deposition of one or more immunoglobulins was noted in all but one patient studied with immunofluorescence. Corresponding electron-dense deposits were seen by electron microscopy in 78% of specimens. Prednisone did not induce a remission of nephrotic syndrome in the 13 patients treated, whereas cyclosporine did so in the 3 patients to whom it was administered. Five patients were in the end stage of renal disease within 8 months. Successful maintenance peritoneal dialysis was performed in three patients, but 80% of patients have died of human immunodeficiency virus-related complications; one patient was lost to follow-up. We conclude that immune-complex deposition is consistently seen in children with human immunodeficiency virus-associated nephrotic syndrome. This nephrotic syndrome is resistant to steroid therapy, but we observed a remission of the proteinuria with cyclosporine therapy in three patients. For patients with end-stage renal disease, maintenance peritoneal dialysis may improve the quality of life.     

Respiratory failure in children with acquired immunodeficiency syndrome and acquired immunodeficiency syndrome-related complex

Acute respiratory failure has a high mortality in patients with acquired immunodeficiency syndrome (AIDS). This study was undertaken to determine the etiology of acute respiratory failure and the outcome of children with AIDS and AIDS-related complex. Records of 31 children with AIDS or AIDS-related complex admitted to the pediatric intensive care unit for acute respiratory failure throughout a 46-month period were reviewed. Acute respiratory failure was due to Pneumocystis carinii pneumonia in 13, cytomegalovirus pneumonia in six, bacterial pneumonia in five, severe bacterial sepsis in four, Candida pneumonia in two, and a giant cell pneumonia in one patient. In addition, 11/19 patients with acute respiratory failure due to P carinii pneumonia or cytomegalovirus had superinfections with bacteria or Candida. Of the total of 19 primary and secondary bacterial infections, Pseudomonas aeruginosa was responsible in ten and Klebsiella pneumoniae in three children. Five children (16%) survived until pediatric intensive care unit discharge; three died within 6 months. The causes of acute respiratory failure were not significantly different in survivor and nonsurvivor groups. It is concluded that, in addition to P carinii pneumonia and cytomegalovirus pneumonia, bacterial infections (especially due to Pseudomonas and other Gram-negative organisms) are important causes of respiratory failure. The high mortality and grim ultimate prognosis seen may have implications for pediatricians attempting to identify the proper limits of medical intervention for this group of patients.     

Extrapulmonary cryptococcosis in children with acquired immunodeficiency syndrome

There is a paucity of published information available on extrapulmonary cryptococcosis (EC) in children infected with human immunodeficiency virus, the etiologic agent of the acquired immunodeficiency syndrome. We surveyed investigators in pediatric acquired immunodeficiency syndrome around the country regarding their experience with EC. Investigators from 33 (87%) of 38 institutions responded and information on 13 patients from 11 institutions was analyzed. EC was the acquired immunodeficiency syndrome indicator disease in 9 (69%) of 13 patients. Median age was 8 years with a range of 2 to 17 years. Human immunodeficiency virus risk factors were transfusion (5 patients), hemophilia (4 patients) and perinatal exposure (4 patients). Meningitis, seen in 62% of patients, was the most common clinical manifestation. Although 2 patients with fulminant disease died before therapy was started, 10 (91%) of 11 had a clinical response to amphotericin B with or without flucytosine. Our study indicates a spectrum of EC in pediatric human immunodeficiency virus infection ranging from fulminant, fatal fungemia to chronic meningitis and fever of unknown origin. Cryptococcosis was generally not the cause of death in patients who initially responded to amphotericin B therapy. Optimal antifungal therapy, including the role of fluconazole, warrants further study.     

Adrenal suppression in children with the human immunodeficiency virus treated with megestrol acetate

Symptoms and laboratory evidence of adrenal suppression developed in 2 children with the human immunodeficiency virus after megestrol acetate (MA) therapy was discontinued; both required transient glucocorticoid replacement therapy. High-dose corticotropin stimulation testing performed on children with the human immunodeficiency virus treated or not treated with MA showed that baseline and post-corticotropin cortisol levels were extremely low in 7 of 10 treated patients and normal in 10 of 10 members of a control group (P <.01). MA may suppress adrenal function, and replacement glucocorticoids may prevent or relieve associated symptoms at times of severe stress or on discontinuation of MA therapy.     

艾滋病2例

例1,女,5岁,因发热、腹泻、呕吐2个月入院。2个月前因发热、腹胀,在当地医院治疗,诊断为结核性腹膜炎。经异烟肼、利福平及头孢曲松钠治疗后腹水消失。体温不降,出现脓血便、呕吐。大便红细胞5~10个／HP,白细胞10~13个／HP。脑脊液细胞总数3600×106／L,中性0.86,淋巴     

Science and ethics of human immunodeficiency virus/acquired immunodeficiency syndrome controversies in Africa

The human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic in Africa has raised important ethical issues for both researchers and clinicians. The most notorious controversy has been related to the zidovudine (AZT) trials in Africa in the late 1990s, in which the control groups were given a placebo rather than an effective drug to prevent vertical transmission. This raised concerns in the sponsoring country about exploitation of subjects, injustice and an ethical double standard between donor countries and resource-poor settings. However, the real double standard is between clinical practice standards in Western versus African countries, which must be addressed as part of the increasing global inequity of wealth both between countries and also within countries. There are important limitations to ethical declarations, principles and guidelines on their own without contextual ethical reasoning. The focus on research ethics with the HIV epidemic has led to a relative neglect of ethical issues in clinical practice. Although the scientific advances in HIV/AIDS have changed the ethical issues since the 1990s, there has also been progress in the bioethics of HIV/AIDS in terms of ethical review capability by local committees as well as in exposure to ethical issues by clinicians and researchers in Africa. However, serious concerns remain about the overregulation of research by bureaucratic agencies which could discourage African research on specifically African health issues. There is also a need for African academic institutions and researchers to progressively improve their research capacity with the assistance of research funders and donor agencies.     

Acquired circulating anticoagulants in children with acquired immunodeficiency syndrome

The mechanism underlying the prolonged activated partial thromboplastin time (APTT) seen in some pediatric patients with acquired immunodeficiency syndrome (AIDS) and opportunistic infections was studied. A circulating inhibitor of coagulation was demonstrated in three patients. The inhibitor appears to be an immunoglobulin that interferes with some of the phospolipid-dependent coagulation reactions of the intrinsic pathway. This "AIDS anticoagulant" does not predispose the patient to clinical bleeding despite its ability to cause a marked prolongation of the APTT. As such, careful laboratory diagnosis of the cause of abnormal coagulation test results is necessary for children with AIDS.     

Acquired immunodeficiency syndrome in older children

The authors report 3 cases of AIDS in children 10 and 11 years of age. These cases fulfill the definition of AIDS such as established by C.D.C. (Centers for Disease Control, Atlanta, Georgia U.S.A.) As opportunistic infections, the first case had oral moniliasis, the second case presented with ganglionic form of Kaposi Sarcoma and the third case had cryptococcal meningitis. The mode of transmission in this age group is unknown. Only one child had repeated transfusion. The parents of these children are in good health and were not at risk for AIDS.     

Nontuberculous mycobacteria in children with acquired immunodeficiency syndrome.

Among 139 children with acquired immunodeficiency syndrome at Children's Hospital of New Jersey, 20 had positive cultures for non-tuberculous mycobacteria. Eighty-five percent had Mycobacterium avium complex isolated and 70% had definite evidence of disseminated disease. Ninety-three percent had CD4 lymphocyte counts less than 100 cells/mm3 and 95% had met acquired immunodeficiency syndrome criteria before the time of first positive culture. Clinical findings included failure to gain weight, anorexia, fever, abdominal pain/tenderness and anemia. The median age at onset of symptoms was 46 months and the median time between onset of symptoms and positive culture was 9 months. Outcome for patients with positive cultures for nontuberculous mycobacteria was poor, with 75% of the children surviving for less than or equal to 10 months. Nontuberculous mycobacteria are increasingly important causes of morbidity and indirect mortality in human immunodeficiency-infected children. Children with severe immunodeficiency are at particular risk. In addition to M. avium complex, other species of nontuberculous mycobacteria may be involved.     

Pediatric human immunodeficiency virus infection and the acquired immunodeficiency syndrome. A health care crisis of children and families

The number of children infected with the human immunodeficiency virus (HIV) is rapidly increasing. Most infected children acquire their infection by vertical transmission from an infected mother, and this increase in the number of infected children reflects a similar increase in the number of infected women. Many features of HIV infection in children differ from those in adults, and it is important for the physician to be familiar with the varied presentations of pediatric HIV infection. Transmission of HIV during adolescence, by sexual contact and illicit drug use, is also a growing problem, accounting for most cases of acquired immunodeficiency syndrome (AIDS) seen in young adults in their 20's. The HIV-infected child represents only one member of a family affected by the HIV virus; frequently, multiple other members of the family are infected as well. These families are predominantly underpriviledged, coming from inner city minority populations with limited access to medical care and social service support. Pediatric AIDS is a preventable disease, by the prevention of HIV infection in women. In short term, it is likely that education will have the greatest impact on altering the course of the AIDS epidemic. Most infected children are cared for in a limited number of public inner city hospitals, and the ability of these hospitals to continue to provide adequate care will be threatened by the rising number of cases. A multidisciplinary approach to providing care for these children and their families is essential, with the primary care physician coordinating this effort. Rapid advances in the treatment of HIV and its associated opportunistic diseases raise difficult questions concerning the access of women, including pregnant women, and children to clinical trials of investigational agents. The commitment of individual health care workers and an increased level of financial support will be necessary to provide the care that these children and their families require and deserve.     

Epstein-Barr virus infection in a child with acquired immunodeficiency syndrome

A 3-year-old girl, born to an intravenous-drug-dependent mother, had protracted diarrhea, failure to thrive, generalized lymphadenopathy, and recurrent fevers during the first six months of life. At 7 months of age, the Epstein-Barr virus (EBV) genome was detected in her saliva by DNA dot-blot hybridization using a cloned EBV probe. Spontaneous EBV+ lymphoblastoid cell lines had repeatedly developed from her peripheral blood lymphocytes over the subsequent 2 1/2 years. At 11 months of age, persistent tachypnea and a diffuse pulmonary infiltrate developed. Lung biopsy demonstrated a florid, peribronchiolar lymphocytic infiltrate and the EBV genome was identified in the lung tissue. Serum anti-EBV antibodies remained undetectable until 14 months of age. She had a T4+/T8+ ratio of less than 0.8 and serum antibody to human T-cell lymphotropic virus type III. The delayed seroresponse of this patient to symptomatic EBV infection suggests that reliance on EBV serology to diagnose EBV infection in immunocompromised hosts may be inappropriate, and other methods such as DNA probes should be used.     

Effect of maternal CD4 cell count, acquired immunodeficiency syndrome, and viral load on disease progression in infants with perinatally acquired human immunodeficiency virus type 1 infection

Among a cohort of 152 infants perinatally infected with human immunodeficiency virus type 1, and their mothers, we correlated infant outcome with maternal CD4 ⁺ lymphocyte count and the presence of maternal acquired immunodeficiency syndrome near delivery. In a subset of 50 mother-infant pairs, we also correlated infant outcome with maternal quantitative viral burden as measured by the nucleic acid sequence based amplification system. We found that low maternal CD4 ⁺ cell count and high viral burden were associated with decreased time to category C disease or death in infants infected with human immunodeficiency virus type 1. In a multivariate analysis, high maternal viral load and maternal acquired immunodeficiency syndrome were independently associated with shorter time to category C disease or death in infants with human immunodeficiency virus type 1 infection. High viral load in pregnant women, independent of the presence of advanced maternal disease, appears to increase the risk of rapidly progressive disease in their infected offspring. (J Pediatr 1997;130:830-7)